News
SEEL
0.9902
+2.08%
0.0202
Weekly Report: what happened at SEEL last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at SEEL last week (0212-0216)?
Weekly Report · 02/19 12:51
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Can Psychedelics Increase Sexual Interest And Satisfaction? Study Says Yes And Effects Can Last Months. A new study suggests a potential link between the use of psychedelics and improved sexual function up to six months after a psychedelic experience. FDA Reviews MDMA Therapy for PTSD, Accepts New Drug Application. A majority of Canadians view psilocybin therapy as a reasonable medical choice for end-of-life distress.
Benzinga · 02/15 13:36
Psychedelic stocks gain after FDA priority review for MDMA therapy
Psychedelic stocks gain after FDA priority review for MDMA therapy. If approved, MDMA could become the first psychedelic-assisted therapy. The new drug application seeks approval of MDMA for post-traumatic stress disorder. The FDA has set a target action date of August 11, 2024 for its review.
Seeking Alpha · 02/12 17:13
'FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says' - Marijuana Moment
The FDA has granted priority review to a drug application for MDMA-assisted therapy for post-traumatic stress disorder. The application has been granted priority status and is expected to be reviewed by August 11. MDMA is a potential treatment option for PTSD in combination with psychotherapy. It would be the first psychedelic in history to be approved as a pharmaceutical.
Benzinga · 02/12 16:38
Weekly Report: what happened at SEEL last week (0205-0209)?
Weekly Report · 02/12 12:35
Weekly Report: what happened at SEEL last week (0129-0202)?
Weekly Report · 02/05 12:48
Seelos Therapeutics Issues Common Warrants to Investors
TipRanks · 01/31 09:33
Seelos Therapeutics Strikes $4M Direct Offering Deal
TipRanks · 01/31 09:33
Weekly Report: what happened at SEEL last week (0122-0126)?
Weekly Report · 01/29 12:29
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New Study Reveals Suggestibility’s Role In Antidepressant Effects Of Psilocybin Therapy. European Union Allocates Funds To Study Psychedelics For Pulmonary Disorder, Multiple Sclerosis, ALS, Parkinson's. Australian Psychiatrists provide first Psychedelic-Assisted Medical Treatments in 50 years.
Benzinga · 01/27 15:00
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
The Global Drug Survey has officially launched its 2024 edition. UK's first regular drug testing service to open in Bristol. The latest issue of the journal Psychedelic Medicine is out. University of Texas and Clusterbusters are conducting a survey on cluster headache medication and psychedelic use.
Benzinga · 01/26 17:33
Seelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of Shares
NASDAQ · 01/26 14:37
Seelos Therapeutics announces equity and warrants offering of $4M
Seelos Therapeutics announces equity and warrants offering of $4M. Shares -6.7% premarket. The company has entered into a direct offering of 3,404,256 common shares and unregistered common warrants. Seelos will use the net proceeds of the offering for general corporate purposes.
Seeking Alpha · 01/26 13:41
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Seelos Therapeutics (SEEL)
TipRanks · 01/23 13:30
Seelos Therapeutics Inc: Current report
Press release · 01/22 16:04
Seelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDA
NASDAQ · 01/22 13:31
Seelos Therapeutics Announces Receipt Of Minutes From Its End Of Phase II Meeting With The U.S. FDA Highlighting Modifications To The Primary And Secondary Endpoints Of Its Phase II Study Of SLS-002
Company plans to continue its previously announced potential partnership discussions and expects to proceed to Phase III with SLS-002 in Adults with Major Depressive Disorder (MDD) at Imminent Risk of Suicide. Seelos received minutes from its End of Phase II Meeting with the FDA. The FDA agreed that the primary endpoint in a Phase III trial could be the suicidality scale.
Benzinga · 01/22 13:01
More
Webull provides a variety of real-time SEEL stock news. You can receive the latest news about Seelos Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SEEL
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing programs include SLS-004, SLS-006, and SLS-007.